Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 4:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 10,816 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Developmental Defect Clear all
Completed No phase listed Observational

Prediction of Brain Injury in Premature Infants

NCT02814383
View directory record Official record
Conditions
Intraventricular Hemorrhage, Periventricular Leukomalacia, Brain Injury, Extreme Prematurity
Interventions
Brain Monitoring Platform
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
0 Hours to 12 Hours
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 31, 2026, 4:52 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

NCT04172441
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
dasiglucagon, Placebo
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
7 Days to 364 Days
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 31, 2026, 4:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Alpha-1 Foundation Research Registry

NCT00499941
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
Not listed
Lead sponsor
Medical University of South Carolina
Other
Eligibility
Not listed
Enrollment
6,655 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 31, 2026, 4:52 AM EDT
Completed Phase 3 Interventional Results available

A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)

NCT02414841
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Vonapanitase, Placebo
Drug
Lead sponsor
Proteon Therapeutics
Industry
Eligibility
18 Years to 100 Years
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 31, 2026, 4:52 AM EDT
Completed No phase listed Observational

The Role of Family Functioning in Adaptation to Being a Caregiver of an Individual With Rett Syndrome

NCT00891956
View directory record Official record
Conditions
Rett Syndrome
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 31, 2026, 4:52 AM EDT
Completed Phase 1 Interventional

Single Dose Pharmacokinetic (PK) Study

NCT03109756
View directory record Official record
Conditions
Angelman Syndrome, Fragile X Syndrome
Interventions
OV101
Drug
Lead sponsor
Ovid Therapeutics Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Chicago, Illinois • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 30, 2017 · Synced Oct 31, 2026, 4:52 AM EDT
Completed No phase listed Observational Results available

Observational Study of OCT in a Patients Undergoing FFR

NCT01663896
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
OCT stent guidance
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
15
States / cities
Birmingham, Alabama • La Jolla, California • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2020 · Synced Oct 31, 2026, 4:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers

NCT05730842
View directory record Official record
Conditions
Healthy Volunteer, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, Inborn
Interventions
EDG-5506 Tablet, Radiolabeled EDG-5506 Suspension, Radiolabeled EDG-5506 Intravenous
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 31, 2026, 4:52 AM EDT
Completed Not applicable Interventional

BEATS 2: Music Therapy in Sickle Cell

NCT03233269
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Music Therapy
Behavioral
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 35 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Oct 31, 2026, 4:52 AM EDT
Withdrawn Phase 2 Interventional

Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome

NCT01475383
View directory record Official record
Conditions
Tourette's Syndrome
Interventions
PF-03654746, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Oct 31, 2026, 4:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of Antimicrobial Peptides in Host Defense Against Vaccinia Virus

NCT00407069
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
286 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Oct 31, 2026, 4:52 AM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia

NCT00005802
View directory record Official record
Conditions
Leukemia
Interventions
aldesleukin, filgrastim, therapeutic allogeneic lymphocytes, cytarabine, etoposide, fludarabine phosphate, methotrexate, mitoxantrone hydrochloride, therapeutic hydrocortisone, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 31, 2026, 4:52 AM EDT
Recruiting No phase listed Observational

Pancreas Registry and High Risk Registry

NCT02775461
View directory record Official record
Conditions
Pancreas Cancer, Pancreatitis, Chronic Pancreatitis, Pancreatic Cyst, Family History of Pancreas Cancer, Genetic Mutations
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
1,368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2033
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 31, 2026, 4:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Evaluate Safety, of NextraTM in Surgery to Fuse the Proximal-interphalangeal- Joints

NCT01604070
View directory record Official record
Conditions
Foot Diseases
Interventions
Not listed
Lead sponsor
eMedtrain Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
4
States / cities
Cambridge, Massachusetts • Vineland, New Jersey • Alexandria, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Oct 31, 2026, 4:52 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

NCT00685373
View directory record Official record
Conditions
Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease
Interventions
Canakinumab (ACZ885)
Drug
Lead sponsor
Novartis
Industry
Eligibility
3 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Little Rock, Arkansas • San Francisco, California • Columbus, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 31, 2026, 4:52 AM EDT
Not yet recruiting No phase listed Observational

Occlutech AFR Fontan Study

NCT07532369
View directory record Official record
Conditions
Failure of Fontan Type Circulation, Fenestration, Univentricular Heart, Congenital Anomaly
Interventions
Occlutech Atrial Flow Regulator Retrospective Data Collection
Device
Lead sponsor
Occlutech International AB
Industry
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
7
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 31, 2026, 4:52 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia

NCT05063994
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Chronocort, Cortef, Placebo
Drug · Other
Lead sponsor
Neurocrine UK Limited
Industry
Eligibility
16 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
11
States / cities
Los Angeles, California • Orange, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 31, 2026, 4:52 AM EDT
Withdrawn No phase listed Observational

The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)

NCT04214002
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa
Interventions
Not listed
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Oct 31, 2026, 4:52 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study

NCT03298867
View directory record Official record
Conditions
Thyroid Eye Disease, Graves' Orbitopathy
Interventions
Teprotumumab, Placebo
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
9
States / cities
Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 31, 2026, 4:52 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

OCT in Diagnosis of Irregular Corneas

NCT03504800
View directory record Official record
Conditions
Keratoconus, Corneal Opacity, Corneal Dystrophy
Interventions
Optical Coherence Tomography
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
14 Years to 85 Years
Enrollment
445 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2031
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 31, 2026, 4:52 AM EDT
Completed Not applicable Interventional

GoalKeeper: Intelligent Information Sharing for Children With Medical Complexity

NCT03620071
View directory record Official record
Conditions
Childhood Cancer, Cerebral Palsy, Chronic Lung Disease, Congenital Heart Disease, Congenital Metabolic Disorder, Gastrostomy
Interventions
GoalKeeper, Standard Care
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 31, 2026, 4:52 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia

NCT04117711
View directory record Official record
Conditions
Classic Galactosemia
Interventions
AT-007, Placebo
Drug
Lead sponsor
Applied Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
4
States / cities
Anaheim, California • Atlanta, Georgia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 31, 2026, 4:52 AM EDT
Completed Phase 1 Interventional

A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A

NCT02920398
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
turoctocog alfa pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Torrance, California • Iowa City, Iowa • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Oct 31, 2026, 4:52 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis

NCT04562116
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Nemolizumab, CYP 450 Substrates
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
North Hollywood, California • Hallandale, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 31, 2026, 4:52 AM EDT